

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Monoamine oxidase A (MAO-A)	<p>Mouse and human sample studies suggest inhibiting MAO-A could help prevent prostate cancer growth and metastasis. In mouse xenograft models of prostate cancer, shRNA against MAO-A or a small molecule inhibitor of MAO-A suppressed metastasis and decreased tumor frequency and growth compared with control shRNA or saline. In human prostate cancer samples, elevated MAO-A levels correlated with higher clinical grade tumors, cancer recurrence and decreased survival. Next steps could include designing small molecule-based strategies to inhibit MAO-A in patients with prostate cancer.</p> <p>Krenitsky Pharmaceuticals Inc. has the reversible MAO-A inhibitor TriRima (KP157) in Phase II testing to treat anxiety and depression.</p> <p>SciBX 7(26); doi:10.1038/scibx.2014.764 Published online July 10, 2014</p>	Patent and licensing status unavailable	<p>Wu, J.B. <i>et al. J. Clin. Invest.</i>; published online May 27, 2014; doi:10.1172/JCI70982 Contact: Leland W.K. Chung, Cedars-Sinai Medical Center, Los Angeles, Calif. e-mail: leland.chung@cshs.org Contact: Haiyen E. Zhau, same affiliation as above e-mail: haiyen.zhau@cshs.org Contact: Jean C. Shih, University of Southern California, Los Angeles, Calif. e-mail: jshih@usc.edu</p>